In this Issue:
Afatinib for EGFR mutation-positive NSCLC
Icotinib promising in pretreated, advanced NSCLC
The value of high adherence to tamoxifen
Improvements in PPS and OS in gastric cancer
Adding cetuximab to DOCOX in mGC: minimal value
Apatinib an option for heavily pretreated mGC
Cost-effectiveness of SBRT vs lobectomy in stage I NSCLC
SBRT has potential in multiple primary lung cancer
Fluorescence imaging of colorectal liver metastases
Panitumumab in mCRC: assess RAS mutation status
Please login below to download this issue (PDF)